Abstract: The present invention concerns an enzymatic process for the preparation of an ingredient comprising triacylglycerols enriched either in palmitic acid at sn-2 position or in oleic acid at sn-2 position.

Abstract: The present invention concerns an enzymatic process for the preparation of a triglyceride ingredient comprising triglycerides present in human breast milk.

Abstract: The present invention concerns an enzymatic process for the preparation of an ingredient comprising 1,3-Olein-2-palmitin (OPO), the most abundant triglyceride present in human breast milk. This is achieved by using immobilized lipase from Ther-momyces lanuginosis for producing 1,3-olein-2-palmitin (1,3-Dioleate-2-palmitate-glycerol) using as substrate tripalmitin or triglycerides enriched in palmitic acid at SN-2 position by first alcoholysis in presence of C3 to C5 alcohol (butanol, pentanol, isopropanol) to produce 2-monopalmitin which is purified by selective crystallization at decreased temperature, followed by esterification using the same lipase and oleic acid.

Abstract: Use of a compound having the formula (1) (2) (3) (4) or combinations thereof, for providing a source of butyrate with improved organoleptic properties wherein R1, R2, R3, R4, R5 and R6 are independently a long chain fatty acid having between 16 and 20 carbons for use in recovery from antibiotic mediated gut microbiota disturbance and/or preventing and/or treating gastrointestinal infections.

Abstract: Use of a compound having the formula (1) (2) (3) (4) or, or combinations thereof, for providing a source of butyrate with improved organoleptic properties wherein R1, R2, R3, R4, R5 and R6 are independently a long chain fatty acid having between 16 and 20 carbons for use in promoting immune response and/or preventing and/or treating bacterial and/or viral infections.

Abstract: A nutritional composition for providing a source of butyrate or butyric acid comprising a compound having the formula (1) wherein R6 is along chain fatty acid having between 16 and 20 carbons.

Abstract: A compound having the formula (1), (2), (3), or (4), or combinations thereof, for use to maintain or increase muscle function and/or mass in a subject, and/or prevent or reduce muscle wasting in a subject, wherein R1, R2? R3, R4, R5 and R6 are independently, a long chain fatty acid having between 16 and 20 carbons.

Abstract: 1. Use of a compound having the formula (1) (2) (3) or (4) or combinations thereof, for use in promotion of bone growth and/or prevention and/or treatment of bone disorders associated to bone growth impairment wherein R1, R2, R3, R4, R5 and R6 are independently a long chain fatty acid having between 16 and 20 carbons.

Abstract: Use of a compound having the formula (1), formula (2), formula (3) or formula (4), or combinations thereof, for promoting and/or accelerating myelination, wherein R1, R2, R3, R4, R5 and R6 are independently a long chain fatty acid having between 16 and 20 carbons.

Abstract: Use of a compound having the formula (1), (2), (3) or (4) or combinations thereof, for use in maintenance of bone health and/or prevention, and/or treatment of bone disorders associated to unbalanced bone catabolism wherein R1, R2, R3, R4, R5 and R6 are independently a long chain fatty acid having between 16 and 20 carbons.

Abstract: A compound having the formula (1), (2), (3) or (4), or combinations thereof, for use in the treatment or prevention of cardiovascular disorders in a subject, wherein R1, R2, R3, R4, R5 and R6 are independently, a long chain fatty acid having between 16 and 20 carbons.

Abstract: Use of a compound having the formula (1), (2), (3) or (4), or combinations thereof, for providing a source of butyrate with improved organoleptic properties wherein R1, R2, R3, R4, R5 and R6 are independently a long chain fatty acid having between 16 and 20 carbons the prevention and/or treatment of non alcoholic fatty liver disease.

Abstract: Use of a compound having the formula (1), (2), (3), or (4) or combinations thereof, for providing a source of butyrate with improved organoleptic properties wherein R1, R2, R3, R4, R5 and R6 are independently a long chain fatty acid having between 16 and 20 carbons the prevention and/or treatment of metabolic disorders.

Abstract: 1.

Abstract: Use of a compound having the formula (1) (2) (3) or (4) or combinations thereof, for increasing blood ketone levels, and/or treating a disease treatable by increasing blood ketone levels, preferably wherein the disease is selected from the list consisting of: a brain energy deficiency condition, a neurological condition, migraine, memory disorder, age-related memory disorder, brain injury, stroke, amyloid lateral sclerosis, multiple sclerosis, cognitive impairment, cognitive impairment post-intensive care, age-induced cognition impairment, Alzheimer's disease, Parkinson's disease, Huntingdon's disease, inherited metabolic disorders (such as glucose transporter type 1 deficiency syndrome and pyruvate dehydrogenase complex deficiency), depression, schizophrenia, epilepsy, narcolepsy, diabetes, obesity, non-alcoholic fatty liver disease and polycystic ovary syndrome, wherein R1, R2, R3, R4, R5 and R6 are independently a long chain fatty acid having between 16 and 20 carbons.

Abstract: A compound having the formula or combinations thereof, for use in the treatment or prevention of an allergic disorder, wherein R1, R2, R3, R4, R5 and R6 are independently, a long chain fatty acid having between 16 and 20 carbons.

Abstract: A composition comprising a compound having the formula (1), (2), (3), (4) or combinations thereof, wherein n1, n2, n3, n4, n5 and n6 are independently 4 to 10.

Abstract: The present invention concerns a highly selective process for the preparation of an ingredient comprising 1,3-Olein-2-palmitin (OPO), a triglyceride present in human breast milk. The present invention also relates to 1,3-Olein-2-palmitin (OPO) ingredient obtainable by the process.

Abstract: A compound having the formula (1), (2), (3) or (4), or combinations thereof, for use in the prevention or treatment of dehydration, and/or in the treatment of diarrhea, wherein R1, R2, R3, R4, R5 and R6 are independently, a long chain fatty acid having between 16 and 20 carbons.

Abstract: Compositions can comprise the catechin metabolite 3?-O-methyl-5-O-sulfate epicatechin. In some embodiments, the composition can be used in a method for blood vessel dilation and/or increased delivery of blood flow to tissues in the body, for example by administering the composition to an individual having or at risk of high blood pressure or a cardiovascular disease. In some embodiments, the compositions are used for weight maintenance or weight loss. In further embodiments the compositions are used for treating or preventing gestational diabetes mellitus. The compositions are preferably administered orally as a food product in which the 3?-O-methyl-5-O-sulfateepicatechinis present in a concentration of at least 0.01 mg/g of the food product.